Domača stranDRREDDY • NSE
add
Dr Reddy's Laboratories Ltd
Prejšnji trg. dan.
1195,35 ₹
Dnevni razpon
1193,60 ₹ - 1223,20 ₹
Letni razpon
1074,00 ₹ - 1421,49 ₹
Tržna kapitalizacija
1,01 bil. INR
Povprečni obseg
1,48 mio.
Razm. P/E
18,96
Dividendna donosnost
0,66 %
Primarna borza
NSE
V novicah
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
(INR) | sep. 2024info | Sprememba L/L |
---|---|---|
Prihodek | 80,16 mrd. | 16,51 % |
Stroški poslovanja | 29,72 mrd. | 24,54 % |
Čisti dohodek | 12,55 mrd. | −15,18 % |
Čista dobičkovnost prihodkov | 15,66 | −27,20 % |
Earnings per share | 15,83 | −11,13 % |
EBITDA | 22,02 mrd. | 8,53 % |
Efektivna davčna stopnja | 30,01 % | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
(INR) | sep. 2024info | Sprememba L/L |
---|---|---|
Denar. in kratkor. naložbe | 63,07 mrd. | −7,15 % |
Skupna sredstva | 465,96 mrd. | 34,27 % |
Skupne obveznosti | 156,67 mrd. | 66,79 % |
Celoten lastniški kapital | 309,28 mrd. | — |
Shares outstanding | 833,05 mio. | — |
Razmerje P/B | 3,26 | — |
Donosnost sredstev | 10,24 % | — |
Donosnost kapitala | 13,21 % | — |
Denarni tok
Neto sprememba denarnih sredstev
(INR) | sep. 2024info | Sprememba L/L |
---|---|---|
Čisti dohodek | 12,55 mrd. | −15,18 % |
Denar iz dejavnosti | 9,32 mrd. | −48,03 % |
Denar iz naložb | −19,07 mrd. | −322,21 % |
Denar iz financiranja | 16,15 mrd. | 329,53 % |
Neto sprememba denarnih sredstev | 6,37 mrd. | 1,03 % |
Prost denarni tok | 3,92 mrd. | −72,47 % |
Vizitka
Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company based in Hyderabad. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology.
Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to other less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe.
By 2007, Dr. Wikipedia
Generalni direktor
Datum ustanovitve
1984
Sedež organizacije
Spletno mesto
Zaposleni
27.048